Mauna Kea Technologies S.A. (MKEA.PA)
Mauna Kea Technologies S.A. operates in the Medical - Devices industry of the Healthcare sector, headquartered in Paris, FR. The stock last traded at $0.62, up 0.32% on the session, giving a market capitalisation of $30.2M. Its beta of 1.44 implies it has historically moved more than the broad market.
Established in 2000 and headquartered in Paris, France, Mauna Kea Technologies S.A. develops and commercializes medical devices across a broad international footprint, encompassing Europe, the Middle East, Africa, the United States, Latin America, and Asia. Its core focus is on developing and distributing innovative instruments for real-time visualization and identification of cellular anomalies during routine gastrointestinal and pulmonary endoscopic procedures. The company's premier offering, Cellvizio, is a sophisticated confocal miniprobe endomicroscopy system that provides clinicians and researchers with ultra-high-resolution images of tissues at a cellular level.
Mauna Kea Technologies S.A. is most often compared with the following Healthcare names: